| Title | Lidocaine: pharmacokinetic approach | |
| Authors | Antonia Kotsiou1 and Ioanna Siafaka2
1. Hosp. Pharm, Ass. Prof. Pharmacology and 2. Assoc. Prof. Anaesthisiology, Aretaieio, University Hospital, Medical School, University of Athens, Hellas |
|
| Citation | Kotsiou, A. and Siafaka, I.: Lidocaine: pharmacokinetic approach, Epitheorese Klin. Farmakol. Farmakokinet. 27(1): 45-47 (2013) | |
| Publication Date | Accepted for publication (Final Version): April 10, 2013 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Lidocaine, pharmacokinetics. | |
| Other Terms | review article | |
| Summary | Binding of drugs to proteins is a key pharmacokinetic parameter for their pharmacological effect. Lidocaine is a widely used local anaesthetic. As a cationic drug binds mainly to alpha1-acid glycolprotein. Upon co-administration with other basic drugs as propranolol, clonidine, diphenydramine, it has been shown to be involved in drug displacement interactions leading to increased serum and tissue lidocaine concentrations. Various situations, e.g. stress, disease, liver and kidney failure, lead also to rise in lidocaine levels, due to alterations in protein concentrations thus interfering to protein binding interactions. These changes should be clinically considered although the pharmacokinetic interactions are in most studied cases not accompanied by changes of pharmacodynamics parameters. | |
| References | 1. Bickel M.H., Gerny R.: Drug distribution as a function of binding competition. Experiments with the distribution dialysis technique. J. Pharm. Pharmacol 32: 669-674 (1980)
2. Kotsiou A., Tesseromatis C.: Protein Binding of Drugs. In: Oral Bioavailability, Basic Principles, Advanced Concepts, and Applications (Ming Hu, Xiaoling Li, eds). Chapter 11, Wiley-Blackwell (Médical), 2011 3. Tesseromatis C., Alevizou A.: The role of the proteinbinding on the mode of drug action as well the interactions with other drugs. Eur. J. Drug Metab. Pharmacokinet 33: 225-230 (2008) 4. Alevizou A., Kotsiou A.: The role of drug-protein binding in the current therapy. Rev. Clin. Pharmacol. Pharmacokinet., Int. Ed. 22 (2 Suppl.): 383-388 (2008) 5. Tesseromatis C., Alevizou A., Tigka E., and A. Kotsiou A.: cute phase proteins – lpha-1- Acid Glycoprotein. In: cute phase proteins – Regulation and Functions of cute phase proteins (Francisco Veas, ed.), Chapter 11. ISBN 978-953-307-252-4 InTech – Open Access Publisher, 2011 6. Tesserommatis C., Tsopanakis C., Varonos D.: Changes in serum lipids with the presence of various factors. Beitr. Infusionsther. 23:195-197 (1988) 7. Tsopanakis C., Tesserommatis C.: Cold swimming stress: effects on serum lipids, lipoproteins and LCAT activity in male and female rats. Pharmacol. Biochem. Behav. 38: 813-816 (1991) 8. Tesserommatis C., Tsopanakis C., Symeonoglou G., Loukissa M., Kouvarou E., Varonos D.D.: How harmless is FFA enhancement? Eur. J. Drug Metab. Pharmacokinet. 21: 213 (1996) 9. Kotsiou A., Alevizou A., Tesseromatis C.: Stress can affect drug pharmacokinetics via serum/tissues protein binding and blood flow rate alterations. Eur. J. Drug Metab. Pharmacokinet. 37: 1-7 (2012) 10. Kotsiou A., Tsamouri M., Anagnostopoulou S., Tzivras M., Vairactaris E., Tesseromatis C.: H3 propranolol serum levels following lidocaine administration in rats with CCl4-induced liver damage. Eur. J. Drug Metab. Pharmacokinet. 31: 97-101 (2006) 11. Droste S.K., Gesing A., Ulbricht S., Muller M.B., Linthorst A.C., Reul J.M.: Effects of long-term voluntary exercise on the mouse hypothalamic-pituitary-adrenocortical axis. Endocrinology 144: 3012-3923 (2003) 12. Tsivou E., Melakopoulos I., Kotsiou A., Anagnostopoulou S., Tesseromatis C.: Alterations in cephalosporin levels in the serum and mandible of hyperlipaedemic rats after co-administration of ibuprofen. Eur. J. Drug Metab. Pharmacokinet. 30: 171-174 (2005) 13. Saranteas T., Tesseromatis C., Potamianou A., Mourouzis C., Varonos D.: Stress-induced lidocaine modification in serum and tissues. Eur. J. Drug Metab. Pharmacokinet. 27: 229-232 (2002) 14. Saranteas T., Mourouzis C., Dannis C., Alexopoulos C., Lolis E., Tesseromatis C.: Effect of various stress models on lidocaine pharmacokinetic properties in the mandible after masseter injection. J. Oral Maxillofac. Surg. 62: 858-862 (2004) 15. van Donselaar-van der Pant KA, Buwalda M, van Leeuwen HJ. [Lidocaine: local anaesthetic with systemic toxicity]. Ned. Tijdschr. Geneeskd. 152: 61-65 (2008) 16. Marra D.E., Yip D., Fincher E.F., Moy R.L.: Systemic toxicity from topically applied lidocaine in conjunction with fractional photothermolysis. Arch. Dermatol. 142: 1024-1026 (2006) 17. Holub P., Svec P., Seginko J.: Acid-base balance disturbance following toxic doses of local anesthetics. Drug Metabol. Drug Interact. 9: 321-331 (1991) 18. Shioiri H., Komaru T., Sato K., Takahashi K., Takeda S., Kanatsuka H., Watanabe J., Shirato K.: Impact of hypercholesterolemia on acidosis-induced coronary microvascular dilation. Basic Res. Cardiol. 98: 76-83 (2003) 19. Svedberg J., Björntorp P., Lönnroth P., Smith U.: (1991) Prevention of inhibitory effect of free fatty acids on insulin binding and action in isolated rat hepatocytes by etomoxir. Diabetes 40: 783-786 (1991) 20. Karakitsos D., Karabinis A., Kotsiou A.: Changes of lidocaine levels in rat serum and tissue under stress and hyperlipidaemic diets. Eur. J. Drug Metab. Pharmacokinet. 34: 143-146 (2009) 21. Benedek I.H., Blouin R.A., McNamara P.J.: Serum protein binding and the role increased alpha 1-acid glycoprotein in moderately obese male subjects. Br. J. Clin. Pharmacol. 18: 941-946 (1985) 22. Klein J.A., Kassarjdian N.: Lidocaine toxicity with tumescent liposuction. Derm. Surg. 23: 1169-1174 (1997) 23. Tesseromatis C., Kotsiou A., Tsagataki M., Tigka E., Vovou J., Alevizou A., Perisanidis C., Saranteas T., Karakitsos D., Karabinis A., Kostopanagiotou G.: In vitro binding of lidocaine to liver tissue under the influence of propranolol: another mechanism of interaction? Eur. J. Drug Metab. Pharmacokinet. 32: 213-217 (2007) 24. Ochs H.R., Carstens G., Greenblatt D.J.: Reduction in lidocaine clearance during continuous infusion and by co-administration of propranolol. N. Engl. J. Med.14: 373-377 (1980) 25. Saranteas T., Mourouzis C., Koumoura F., Tesseromatis C.: Effects of propranolol or paracetamol on lidocaine concentrations in serum and tissues. J. Oral Maxillofac. Surg. 61: 604-607 (2003) 26. MacPherson R.D.: The pharmacological basis of contemporary pain management. Pharmacol. Ther. 88: 163-185 (2000) 27. Tigka E., Saranteas T., Mourouzis I., Kotsiou A.: The influence of clonidine co-administration on the extent of lidocaine protein binding to rat serum and tissues. J. Oral Sci. 53: 61-66 (2011) 28. Tigka E., Kotsiou A., Saranteas, T., Mourouzis, J., Kostopanagiotou, G., Tesseromatis C.: Clonidine changes lidocaine free concentrations in rat myocardium without affecting heart function measured by echocardiography. Eur. J. Drug Metab. Pharmacokinet. 34: 229-232 (2009) 29. Yokoyama M., Hirakawa M., Goto H: Clonidine does not affect lidocaine seizure threshold in rats. Can. J. Anesth. 40: 1205-1209 (1993) 30. Tigka E., Alevizou A., Kotsiou A., Tesseromatis C.: The influence of diphenhydramine administration on lidocaine protein binding in rat serum and tissues. Int. J. Pharmacol. 7: 880-883 (2011) |
|
| Relative Papers |
Online ISSN 1011-6575